PAREXEL EXPERTS TO ADDRESS APPROACHES TO ACCELERATE EARLY PHASE DEVELOPMENT DECISIONS AT ASCPT ANNUAL MEETING
Boston, MA, March 12, 2012—PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that Klaus Franke, M.D., Global Medical Affairs Consultant and Dr. John Lambert MBBS, Ph.D., MMed, Chief Medical Officer, Early Phase at PAREXEL will present a poster regarding the application of disease models in early phase development at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, to be held March 12-17, 2012 in Maryland. The poster will be delivered during Poster Session I at 8:00 a.m. on Thursday, March 15.
PAREXEL experts will be available at Booth 129 in the exhibit hall to discuss how biomarkers are increasingly important in early phase development to help biopharmaceutical companies make better, faster decisions about their compounds. The Company provides access to key biomarkers in major disease categories, bioanalytical services, and an extensive database with more than 500 internally developed and validated analytical methods that adhere to ICH and FDA guidelines.
A dedicated team of PAREXEL experts provides scientific, therapeutic and regulatory expertise to design and implement proof of concept studies to help biopharmaceutical companies obtain early signals of safety and efficacy. PAREXEL offers customized solutions including the appropriate use of biomarkers and adaptive trial designs, supported by specialized biostatistical expertise and eClinical technology capabilities.
For more information about PAREXEL early phase capabilities visit: http://www.parexel.com/services-and-capabilities/early-phase.
More information about the ASCPT meeting can be found at: http://www.ascpt.org/2012AnnualMeeting/tabid/8104/Default.aspx.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2011 as filed with the SEC on February 9, 2012, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.